

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal61lhxl

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the  
present  
NEWS 4 DEC 08 INPADOC: Legal Status data reloaded  
NEWS 5 SEP 29 DISSABS now available on STN  
NEWS 6 OCT 10 PCTFULL: Two new display fields added  
NEWS 7 OCT 21 BIOSIS file reloaded and enhanced  
NEWS 8 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced  
NEWS 9 NOV 24 MSDS-CCOHS file reloaded  
NEWS 10 DEC 08 CABA reloaded with left truncation  
NEWS 11 DEC 08 IMS file names changed  
NEWS 12 DEC 09 Experimental property data collected by CAS now available  
in REGISTRY  
NEWS 13 DEC 09 STN Entry Date available for display in REGISTRY and CA/CAPLUS  
NEWS 14 DEC 17 DGENE: Two new display fields added  
NEWS 15 DEC 18 BIOTECHNO no longer updated  
NEWS 16 DEC 19 CROPU no longer updated; subscriber discount no longer  
available  
NEWS 17 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS  
databases  
NEWS 18 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields  
NEWS 19 DEC 22 ABI-INFORM now available on STN  
NEWS 20 JAN 27 Source of Registration (SR) information in REGISTRY updated  
and searchable  
NEWS 21 JAN 27 A new search aid, the Company Name Thesaurus, available in  
CA/CAPLUS  
NEWS 22 FEB 05 German (DE) application and patent publication number format  
changes  
  
NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:10:51 ON 13 FEB 2004

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:11:03 ON 13 FEB 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 FEB 2004 HIGHEST RN 649538-27-2

DICTIONARY FILE UPDATES: 11 FEB 2004 HIGHEST RN 649538-27-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003



Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10088769.str



chain nodes :

13 14 15 16 30 31

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 17 18 19 20 21 22 23 24 25 26 27 28

chain bonds :

6-13 11-13 13-14 13-16 14-15 15-30 16-17 20-23 30-31

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 17-18 17-22 18-19 19-20 20-21 21-22 23-24 23-28 24-25 25-26 26-27 27-28

exact/norm bonds :

02/13/2004

10088768.trn

6-13 11-13 13-14 13-16 14-15 15-30 16-17 17-18 17-22 18-19 19-20 20-21  
20-23 21-22 30-31  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 23-24 23-28  
24-25 25-26 26-27 27-28

G1:C,N


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom  
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom  
30:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10088769.str



chain nodes :

13 14 15 16 30 31

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 17 18 19 20 21 22 23 24 25 26 27  
28

chain bonds :

6-13 11-13 13-14 13-16 14-15 15-30 16-17 20-23 30-31

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 17-18 17-22  
18-19 19-20 20-21 21-22 23-24 23-28 24-25 25-26 26-27 27-28

exact/norm bonds :

6-13 11-13 13-14 13-16 14-15 15-30 16-17 17-18 17-22 18-19 19-20 20-21  
20-23 21-22 30-31

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 23-24 23-28  
24-25 25-26 26-27 27-28

G1:C,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom  
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom  
30:CLASS 31:CLASS

L2        STRUCTURE UPLOADED

=> d 12

L2 HAS NO ANSWERS

L2                STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s 12

SAMPLE SEARCH INITIATED 14:12:38 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        329 TO ITERATE

100.0% PROCESSED        329 ITERATIONS

19 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*  
                              BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:        5492 TO        7668


PROJECTED ANSWERS:            119 TO        641

L3                19 SEA SSS SAM L2

=> d 11

L1 HAS NO ANSWERS

L1                STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=&gt; s l1

SAMPLE SEARCH INITIATED 14:13:08 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 329 TO ITERATE

100.0% PROCESSED 329 ITERATIONS 19 ANSWERS  
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 5492 TO 7668  
 PROJECTED ANSWERS: 119 TO 641

L4 19 SEA SSS SAM L1

=&gt; s l1 ful

FULL SEARCH INITIATED 14:13:15 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 6640 TO ITERATE

100.0% PROCESSED 6640 ITERATIONS 311 ANSWERS  
 SEARCH TIME: 00.00.01

L5 311 SEA SSS FUL L1

=&gt; fil caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
156.68	156.89

02/13/2004

10088768.trn

FILE 'CAPLUS' ENTERED AT 14:13:19 ON 13 FEB 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Feb 2004 VOL 140 ISS 7  
FILE LAST UPDATED: 11 Feb 2004 (20040211/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s 15  
L6 9 L5

=> d abs ibib hitstr 1-  
YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y


16  
AB

ANSWER 1 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN  
Structure-activity relationship (SAR) studies of initial screening hits from our corporate library of compds. and a structurally related series of CCR1 receptor antagonists were used to determine that an N-(alkyl)benzylpiperidine is an essential pharmacophore for selective CCR3 antagonists. Further SAR studies that introduced N-(ureidoalkyl) substituents improved the binding potency of these compds. from the micromolar to the low nanomolar range. This new series of compds. also displays highly potent, in vitro functional CCR3-mediated antagonism of eotaxin-induced Ca<sup>2+</sup> mobilization and chemotaxis of human eosinophils.

ACCESSION NUMBER: 2002:515125 CAPLUS  
DOCUMENT NUMBER: 137:210415  
TITLE: Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists  
AUTHOR(S): De Lucca, George V.; Kim, Ui T.; Johnson, Curt; Vargo, Brian J.; Welch, Patricia K.; Covington, Maryanne; Davies, Paul; Solomon, Kimberly A.; Newton, Robert C.; Trainor, George L.; Decicco, Carl P.; Ko, Soo S.  
CORPORATE SOURCE: Experimental Station, Bristol-Myers Squibb Company, Wilmington, DE, 19880-0336, USA  
SOURCE: Journal of Medicinal Chemistry (2002), 45(17), 3794-3804  
CODEN: JMCMAR; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 193541-48-9P 193541-51-4P 193541-54-7P  
193541-96-7P 455259-43-5P 455259-44-6P  
455259-45-7P 455259-46-8P 455259-47-9P  
455259-48-0P 455259-49-1P 455259-50-4P  
455259-51-5P 455259-52-6P 455259-53-7P  
455259-54-8P 455259-55-9P 455259-56-0P  
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(discovery and structure-activity relationship of N-(ureidoalkyl)benzylpiperidines as CCR3 receptors antagonists)  
RN 193541-48-9 CAPLUS  
CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 193541-51-4 CAPLUS  
CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 193541-54-7 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[2-(1-piperidinyl)ethyl]-(9CI) (CA INDEX NAME)




RN 193541-96-7 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[1-(phenylmethyl)-4-piperidinyl]-(9CI) (CA INDEX NAME)



RN 455259-43-5 CAPLUS


CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(4-hydroxybutyl) (9CI) (CA INDEX NAME)



RN 455259-44-6 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)






RN 455259-45-7 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 455259-46-8 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 455259-47-9 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 455259-48-0 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[2-(4-fluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 455259-49-1 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 455259-50-4 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)




RN 455259-51-5 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 455259-52-6 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 455259-53-7 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 455259-54-8 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 455259-55-9 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(2,5-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 455259-56-0 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-4-pyridinyl- (9CI) (CA INDEX NAME)




IT 193541-41-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(discovery and structure-activity relationship of N-(ureidoalkyl)benzylpiperidines as CCR3 receptors antagonists)

RN 193541-41-2 CAPLUS

CN Carbamic acid, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, phenyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT:

49

THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN  
GI



AB Compds. of general formula [I; wherein Ar1 and Ar2 are each an optionally substituted aromatic group; P and Q are each a divalent aliphatic hydrocarbon group which may contain ethereal oxygen or sulfur in the carbon chain and may be substituted; R1 and R3 are each (i) hydrogen, (ii) acyl, or (iii) optionally substituted hydrocarbyl; R2 and R4 are each (i) hydrogen, (ii) optionally substituted alkyl, or (iii) optionally substituted alkylcarbonyl; alternatively R1 and R2 or R3 and R4 together with the nitrogen atom adjacent thereto may form a monocyclic or fused nitrogenous heterocyclic group; and j is 0 or 1], salts of the same, or prodrugs thereof are prepared. These compds. are useful for the treatment of diseases caused by MCH, e.g. obesity (as antiobesity agents) or overeating (as appetite depressants), or for the improvement of emotional disorders or sexual function. Thus, benzyl 2-[(5-hydroxy-2,2-diphenylpentyl)amino]-2-oxoethylcarbamate was brominated by Br and Ph3P in MeCN at room temperature for 1 h to give benzyl 2-[(5-bromo-2,2-diphenylpentyl)amino]-2-oxoethylcarbamate which was dissolved in MeCN, treated with 4-phenylpiperidine and K2CO3 in MeCN, and stirred at 40° overnight to give, after purification on alumina column chromatog. and conversion into the HCl, benzyl 2-[[2,2-diphenyl-5-(4-phenylpiperidino)pentyl]amino]-2-oxoethylcarbamate hydrochloride (II). II in vitro inhibited the binding of [35S]-guanosine 5'-(γ-thio)triphosphate to human somatostatin-like receptor (SLC-1) with IC50 of 5 nM. Tablet formulations containing II were described. .

ACCESSION NUMBER: 2001:228703 CAPLUS  
DOCUMENT NUMBER: 134:252267  
TITLE: Preparation of diarylalkanediamine derivatives as melanin concentrating hormone (MCH) antagonists  
INVENTOR(S): Kato, Kaneyoshi; Mori, Masaaki; Suzuki, Nobuhiro; Shimomura, Yukio; Takekawa, Shiro; Choh, Nobuo  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
SOURCE: PCT Int. Appl., 284 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021169	A1	20010329	WO 2000-JP6376	20000919
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2000073158 A5 20010424 AU 2000-73158 20000919  
JP 2002097138 A2 20020402 JP 2000-288894 20000919  
EP 1219294 A1 20020703 EP 2000-961076 20000919

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.: JP 1999-266278 A 19990920  
JP 2000-221055 A 20000717  
WO 2000-JP6376 W 20000919

OTHER SOURCE(S): MARPAT 134:252267

IT 331629-15-3P 331629-32-4P 331629-34-6P  
331629-35-7P 331629-45-9P 331629-46-0P  
331629-48-2P 331629-55-1P 331629-56-2P  
331629-81-3P 331630-19-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of diarylalkanediamine derivs. as melanin concentrating hormone (MCH)

antagonists for treating MCH-caused diseases)

RN 331629-15-3 CAPLUS


CN Carbamic acid, [2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



546/234  
514/331


RN 331629-32-4 CAPLUS

CN Benzenepentanamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-8-oxo- (9CI) (CA INDEX NAME)




RN 331629-34-6 CAPLUS

CN Butanoic acid, 4-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 331629-35-7 CAPLUS

CN Acetamide, 2-(acetyloxy)-N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-  
(9CI) (CA INDEX NAME)


RN 331629-45-9 CAPLUS

CN 2-Furancarboxamide, 5-bromo-N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 331629-46-0 CAPLUS

CN 2-Thiophenecarboxamide, 5-bromo-N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 331629-48-2 CAPLUS

CN Benzamide, 3-bromo-N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-  
(9CI) (CA INDEX NAME)




RN 331629-55-1 CAPLUS

CN Carbamic acid, [3-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 331629-56-2 CAPLUS


CN Carbamic acid, [4-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-4-oxobutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 331629-81-3 CAPLUS

CN Glycinamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331630-19-4 CAPLUS

CN Carbamic acid, [2-[[2,2-bis(4-chlorophenyl)-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





IT 179312-63-1P 193541-29-6P 193541-38-7P  
193541-39-8P 193541-41-2P 193542-43-7P  
193546-11-1P 331629-14-2P 331629-19-7P  
331629-24-4P 331629-25-5P 331629-27-7P  
331629-30-2P 331629-31-3P 331629-33-5P  
331629-36-8P 331629-37-9P 331629-38-0P  
331629-39-1P 331629-40-4P 331629-41-5P  
331629-42-6P 331629-43-7P 331629-44-8P  
331629-47-1P 331629-49-3P 331629-50-6P  
331629-51-7P 331629-52-8P 331629-53-9P  
331629-54-0P 331629-57-3P 331629-58-4P  
331629-59-5P 331629-61-9P 331629-62-0P  
331629-63-1P 331629-64-2P 331629-65-3P  
331629-66-4P 331629-67-5P 331629-68-6P  
331629-69-7P 331629-70-0P 331629-71-1P  
331629-72-2P 331629-73-3P 331629-74-4P  
331629-75-5P 331629-76-6P 331629-77-7P  
331629-78-8P 331629-79-9P 331629-80-2P  
331629-82-4P 331629-83-5P 331629-84-6P  
331629-85-7P 331629-86-8P 331629-87-9P  
331629-88-0P 331629-89-1P 331629-90-4P  
331629-91-5P 331629-92-6P 331629-93-7P  
331629-94-8P 331629-95-9P 331629-96-0P  
331629-97-1P 331629-98-2P 331629-99-3P  
331630-00-3P 331630-13-8P 331630-14-9P  
331630-15-0P 331630-16-1P 331630-17-2P  
331630-18-3P 331630-20-7P 331630-21-8P  
331630-22-9P 331630-23-0P 331630-24-1P  
331630-25-2P 331630-26-3P 331630-27-4P  
331630-31-0P 331630-32-1P 331630-33-2P  
331630-34-3P 331630-35-4P 331630-36-5P  
331630-37-6P 331630-38-7P 331630-39-8P  
331630-40-1P 331630-41-2P 331630-42-3P  
331630-43-4P 331630-44-5P 331630-45-6P  
331630-46-7P 331630-47-8P 331630-48-9P  
331630-49-0P 331630-51-4P 331630-52-5P  
331630-53-6P 331630-54-7P 331630-55-8P  
331630-56-9P 331630-57-0P 331630-59-2P  
331630-60-5P 331630-61-6P 331630-62-7P  
331630-63-8P 331630-65-0P 331630-66-1P  
331630-67-2P 331630-68-3P 331630-70-7P  
331630-74-1P 331630-75-2P 331630-77-4P  
331630-81-0P 331630-84-3P 331630-85-4P  
331630-86-5P 331630-87-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylalkanediamine derivs. as melanin concentrating hormone (MCH)

antagonists for treating MCH-caused diseases)

RN 179312-63-1 CAPLUS


CN Formamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193541-29-6 CAPLUS

CN Formamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 193541-38-7 CAPLUS

CN Butanoic acid, 4-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 193541-39-8 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 193541-41-2 CAPLUS

CN Carbamic acid, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 193542-43-7 CAPLUS

CN Butanoic acid, 4-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 193546-11-1 CAPLUS


CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(3-hydroxypropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



HCl


RN 331629-14-2 CAPLUS

CN Carbamic acid, [2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 331629-19-7 CAPLUS


CN Acetamide, N-[4,4-diphenyl-7-(4-phenyl-1-piperidinyl)heptyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 331629-24-4 CAPLUS


CN 2-Thiophenecarboxamide, N-[4,4-diphenyl-7-(4-phenyl-1-piperidinyl)heptyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 331629-25-5 CAPLUS

CN Benzeneacetamide, N-[4,4-diphenyl-7-(4-phenyl-1-piperidinyl)heptyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 331629-27-7 CAPLUS  
 CN 2-Thiophenecarboxamide, N-[4,4-diphenyl-7-(4-phenyl-1-piperidinyl)heptyl]-  
 (9CI) (CA INDEX NAME)




RN 331629-30-2 CAPLUS  
 CN Benzenehexanamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-  
 (9CI) (CA INDEX NAME)



RN 331629-31-3 CAPLUS  
 CN Butanamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-4-  
 (phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 331629-33-5 CAPLUS  
 CN [1,1'-Biphenyl]-4-carboxamide, N-[2,2-diphenyl-5-(4-phenyl-1-  
 piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 331629-36-8 CAPLUS

CN Carbamic acid, [(1S)-2-[[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 331629-37-9 CAPLUS

CN Carbamic acid, [(1S)-1-[[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331629-38-0 CAPLUS

CN Carbamic acid, [(1S)-2-[[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331629-39-1 CAPLUS

CN Carbamic acid, [(1S)-2-[[2,2-diphenyl-5-(4-phenyl-1-piperidiny]pentyl]amino]-1-(hydroxymethyl)-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331629-40-4 CAPLUS

CN Carbamic acid, [(1R)-2-[[2,2-diphenyl-5-(4-phenyl-1-piperidiny]pentyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331629-41-5 CAPLUS


CN 1-Pyrrolidinecarboxylic acid, 2-[[[2,2-diphenyl-5-(4-phenyl-1-piperidiny]pentyl]amino]carbonyl]-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331629-42-6 CAPLUS

CN 2-Thiophenecarboxamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-  
(9CI) (CA INDEX NAME)




RN 331629-43-7 CAPLUS

CN Benzamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-4-  
(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 331629-44-8 CAPLUS

CN Benzamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-4-phenoxy-,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 331629-47-1 CAPLUS


CN 1H-Pyrrole-2-carboxamide, N-[2,2-diphenyl-5-(4-phenyl-1-  
piperidinyl)pentyl]- (9CI) (CA INDEX NAME)






RN 331629-49-3 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 331629-50-6 CAPLUS

CN Benzamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-3-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 331629-51-7 CAPLUS

CN 4-Thiazolecarboxamide, 2-(benzoylamino)-N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 331629-52-8 CAPLUS

CN Benzamide, 4-bromo-N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




546/209


RN 331629-53-9 CAPLUS  
 CN Benzamide, 4-(benzoylamino)-N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 331629-54-0 CAPLUS  
 CN 1,4-Benzenedicarboxamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-N'-phenyl- (9CI) (CA INDEX NAME)




RN 331629-57-3 CAPLUS  
 CN Carbamic acid, [2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]methyl-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 331629-58-4 CAPLUS  
 CN Urea, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 331629-59-5 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 331629-61-9 CAPLUS


CN 1H-Indole-2-carboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



546/201  
514/323


RN 331629-62-0 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 331629-63-1 CAPLUS


CN 2-Benzofurancarboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



546/196  
514/319


RN 331629-64-2 CAPLUS

CN 1H-Indole-2-carboxamide, 5-chloro-N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 331629-65-3 CAPLUS

CN 2-Naphthalenecarboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 331629-66-4 CAPLUS

CN 2-Naphthalenecarboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-1-hydroxy- (9CI) (CA INDEX NAME)




RN 331629-67-5 CAPLUS

CN 2-Naphthalenecarboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-3-hydroxy- (9CI) (CA INDEX NAME)




RN 331629-68-6 CAPLUS

CN Glycinamide, N-phenyl-N-(trifluoroacetyl)glycyl-N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 331629-69-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 331629-70-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 331629-71-1 CAPLUS

CN Benzanamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 331629-72-2 CAPLUS

CN Benzenepropanamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 331629-73-3 CAPLUS

CN Carbamic acid, [2-[[2,2-diphenyl-5-(4-phenyl-1-piperidiny)pentyl]amino]-2-oxoethyl]-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)




RN 331629-74-4 CAPLUS

CN Carbamic acid, [2-[[2,2-diphenyl-5-(4-phenyl-1-piperidiny)pentyl]amino]-2-oxoethyl]-, (4-chlorophenyl)methyl ester (9CI) (CA INDEX NAME)




RN 331629-75-5 CAPLUS

CN Carbamic acid, [2-[[2,2-diphenyl-5-(4-phenyl-1-piperidiny)pentyl]amino]-2-oxoethyl]-, (3-chlorophenyl)methyl ester (9CI) (CA INDEX NAME)




RN 331629-76-6 CAPLUS

CN Benzeneacetamide, 2-[[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidiny)pentyl]amino]-2-oxoethyl]amino]- (9CI) (CA INDEX NAME)




RN 331629-77-7 CAPLUS

CN Carbamic acid, [2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-, (2-chlorophenyl)methyl ester (9CI) (CA INDEX NAME)




RN 331629-78-8 CAPLUS

CN Carbamic acid, [2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-, (4-methoxyphenyl)methyl ester (9CI) (CA INDEX NAME)




RN 331629-79-9 CAPLUS

CN Carbamic acid, [2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-, (3-methoxyphenyl)methyl ester (9CI) (CA INDEX NAME)




RN 331629-80-2 CAPLUS

CN Carbamic acid, [2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-, (2-methoxyphenyl)methyl ester (9CI) (CA INDEX NAME)




RN 331629-82-4 CAPLUS

CN Acetamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidiny)pentyl]-2-[[[(phenylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 331629-83-5 CAPLUS

CN Benzenepentanamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidiny)pentyl]-8-hydroxy- (9CI) (CA INDEX NAME)



RN 331629-84-6 CAPLUS


CN Butanediamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidiny)pentyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 331629-85-7 CAPLUS


CN Benzeneacetamide, N-[3-[[2,2-diphenyl-5-(4-phenyl-1-piperidiny)pentyl]amino]-3-oxopropyl]- (9CI) (CA INDEX NAME)






RN 331629-86-8 CAPLUS

CN Benzamide, N-[4-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-4-oxobutyl]- (9CI) (CA INDEX NAME)




RN 331629-87-9 CAPLUS

CN Carbonic acid, 2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl phenylmethylester (9CI) (CA INDEX NAME)




RN 331629-88-0 CAPLUS

CN 2-Thiophenecarboxamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-5-phenyl- (9CI) (CA INDEX NAME)




RN 331629-89-1 CAPLUS

CN 2-Furancarboxamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-5-phenyl- (9CI) (CA INDEX NAME)



RN 331629-90-4 CAPLUS


CN [1,1'-Biphenyl]-3-carboxamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidiny)pentyl]- (9CI) (CA INDEX NAME)



RN 331629-91-5 CAPLUS


CN Glycinamide, L-phenylalanyl-N-[2,2-diphenyl-5-(4-phenyl-1-piperidiny)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331629-92-6 CAPLUS

CN Carbamic acid, [2-[[2,2-diphenyl-5-(4-phenyl-1-piperidiny)pentyl]methylamino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 331629-93-7 CAPLUS


CN Carbamic acid, [2-[[5-[4-(3-fluorophenyl)-1-piperidiny]-2,2-diphenylpentyl]amino]-2-oxoethyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 331629-94-8 CAPLUS


CN Carbamic acid, [2-[[5-[4-(2-fluorophenyl)-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 331629-95-9 CAPLUS


CN Carbamic acid, [2-[[5-[4-(4-fluorophenyl)-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 331629-96-0 CAPLUS

CN Carbamic acid, [2-[[5-[4-(3-methoxyphenyl)-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 331629-97-1 CAPLUS  
 CN Carbamic acid, [2-[[5-[4-(2-methoxyphenyl)-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 331629-98-2 CAPLUS  
 CN Carbamic acid, [2-[[2,2-diphenyl-5-[4-(4-methoxyphenyl)-1-piperidinyl]pentyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 331629-99-3 CAPLUS  
 CN Carbamic acid, [2-[[2,2-diphenyl-5-[4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]pentyl]amino]-2-oxoethyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 331630-00-3 CAPLUS


CN Carbamic acid, [2-[[5-(4-methyl-4-phenyl-1-piperidinyl)-2,2-diphenylpentyl]amino]-2-oxoethyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 331630-13-8 CAPLUS


CN Carbamic acid, [2-[[[2,2-diphenyl-4-(4-phenyl-1-piperidiny)]butyl]amino]-2-oxoethyl]-, phenylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 331630-14-9 CAPLUS


CN Benzo[b]thiophene-2-carboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




546/202  
514/324

RN 331630-15-0 CAPLUS  
CN 1H-Indole-4-carboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 331630-16-1 CAPLUS  
CN 1H-Indole-5-carboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 331630-17-2 CAPLUS


CN 1H-Indole-6-carboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 331630-18-3 CAPLUS

CN 1H-Indole-7-carboxamide, N-[2-[[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 331630-20-7 CAPLUS  
 CN Carbamic acid, [2-[[2,2-bis(4-chlorophenyl)-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-, (3-chlorophenyl)methyl ester (9CI)  
 (CA INDEX NAME)




RN 331630-21-8 CAPLUS  
 CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-chlorophenyl)-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 331630-22-9 CAPLUS




CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-chlorophenyl)-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)




RN 331630-23-0 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-chlorophenyl)-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 331630-24-1 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-chlorophenyl)-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 331630-25-2 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-chlorophenyl)-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 331630-26-3 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-chlorophenyl)-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 331630-27-4 CAPLUS

CN Acetamide, N-[2-[[2,2-bis(4-chlorophenyl)-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-2-phenoxy- (9CI) (CA INDEX NAME)




RN 331630-31-0 CAPLUS

CN Carbamic acid, [2-[[5-[4-(2-fluorophenyl)-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331630-32-1 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[5-[4-(2-fluorophenyl)-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 331630-33-2 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[5-[4-(2-fluorophenyl)-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 331630-34-3 CAPLUS

CN 1H-Indole-2-carboxamide, 5-chloro-N-[2-[[5-[4-(2-fluorophenyl)-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 331630-35-4 CAPLUS

CN 1H-Indole-2-carboxamide, 5-chloro-N-[2-[[5-[4-(2-fluorophenyl)-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 331630-36-5 CAPLUS

CN Carbamic acid, [2-[[2,2-bis(4-chlorophenyl)-5-[4-(2-fluorophenyl)-1-piperidinyl]pentyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331630-37-6 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-chlorophenyl)-5-[4-(2-fluorophenyl)-1-piperidinyl]pentyl]amino]-2-oxoethyl]-5-fluoro- (9CI) (CA INDEX NAME)




RN 331630-38-7 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-chlorophenyl)-5-[4-(2-fluorophenyl)-1-piperidinyl]pentyl]amino]-2-oxoethyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 331630-39-8 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-chlorophenyl)-5-[4-(2-fluorophenyl)-1-piperidinyl]pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 331630-40-1 CAPLUS

CN Carbamic acid, [2-[[2,2-bis(4-fluorophenyl)-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331630-41-2 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-fluorophenyl)-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 331630-42-3 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-fluorophenyl)-5-(4-phenyl-1-piperidinyl)pentyl]amino]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)




RN 331630-43-4 CAPLUS

CN Carbamic acid, [2-[[2,2-bis(4-fluorophenyl)-5-[4-(2-methoxyphenyl)-1-piperidinyl]pentyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331630-44-5 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-fluorophenyl)-5-[4-(2-methoxyphenyl)-1-piperidinyl]pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)



RN 331630-45-6 CAPLUS


CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-fluorophenyl)-5-[4-(2-methoxyphenyl)-1-piperidinyl]pentyl]amino]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)






RN 331630-46-7 CAPLUS

CN Carbamic acid, [2-[[2,2-bis(4-fluorophenyl)-5-[4-(2-fluorophenyl)-1-piperidinyl]pentyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331630-47-8 CAPLUS

CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-fluorophenyl)-5-[4-(2-fluorophenyl)-1-piperidinyl]pentyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 331630-48-9 CAPLUS


CN 1H-Indole-2-carboxamide, N-[2-[[2,2-bis(4-fluorophenyl)-5-[4-(2-fluorophenyl)-1-piperidinyl]pentyl]amino]-2-oxoethyl]-5-chloro- (9CI) (CA INDEX NAME)



RN 331630-49-0 CAPLUS


CN Formamide, N-[5-[4-(4-fluorophenyl)-1-piperazinyl]-2,2-diphenylpentyl]-  
(9CI) (CA INDEX NAME)544/393  
514/255.03

RN 331630-51-4 CAPLUS

CN Formamide, N-[2-(4-chlorophenyl)-2-phenyl-5-(4-phenyl-1-  
piperidinyl)pentyl]- (9CI) (CA INDEX NAME)


RN 331630-52-5 CAPLUS

CN Formamide, N-[2-(4-chlorophenyl)-2-phenyl-5-(4-phenyl-1-  
piperazinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 331630-53-6 CAPLUS

CN Formamide, N-[2-(4-chlorophenyl)-5-[4-(4-fluorophenyl)-1-piperazinyl]-2-phenylpentyl]- (9CI) (CA INDEX NAME)




RN 331630-54-7 CAPLUS

CN Formamide, N-[2-(4-methoxyphenyl)-2-phenyl-5-(4-phenyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 331630-55-8 CAPLUS


CN Formamide, N-[2,2-bis(4-chlorophenyl)-5-[4-(4-fluorophenyl)-1-piperazinyl]pentyl]- (9CI) (CA INDEX NAME)




RN 331630-56-9 CAPLUS

CN Formamide, N-[6-[4-(4-fluorophenyl)-1-piperazinyl]-2,2-diphenylhexyl]-  
(9CI) (CA INDEX NAME)

RN 331630-57-0 CAPLUS


CN Formamide, N-[6-[4-(4-fluorophenyl)-1-piperazinyl]-3,3-diphenylhexyl]-  
(9CI) (CA INDEX NAME)

RN 331630-59-2 CAPLUS

CN Formamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-  
(9CI) (CA INDEX NAME)


RN 331630-60-5 CAPLUS

CN Formamide, N-[5-(4-hydroxy-4-phenyl-1-piperidinyl)-2,2-diphenylpentyl]-  
(9CI) (CA INDEX NAME)




RN 331630-61-6 CAPLUS

CN Formamide, N-[5-[4-hydroxy-4-[4-(trifluoromethyl)phenyl]-1-piperidinyl]-2,2-diphenylpentyl]- (9CI) (CA INDEX NAME)




RN 331630-62-7 CAPLUS

CN Formamide, N-[5-[4-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]- (9CI) (CA INDEX NAME)




RN 331630-63-8 CAPLUS

CN Formamide, N-[5-[4-(3,5-dichlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]- (9CI) (CA INDEX NAME)




RN 331630-65-0 CAPLUS

CN Formamide, N-[5-[4-(4-chlorophenyl)-1-piperidinyl]-2,2-diphenylpentyl]-  
(9CI) (CA INDEX NAME)




RN 331630-66-1 CAPLUS

CN Formamide, N-[7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-4,4-diphenylheptyl]- (9CI) (CA INDEX NAME)




RN 331630-67-2 CAPLUS

CN Formamide, N-[5-[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]- (9CI) (CA INDEX NAME)




RN 331630-68-3 CAPLUS

CN Formamide, N-[5-[4-hydroxy-4-(4-methoxyphenyl)-1-piperidinyl]-2,2-diphenylpentyl]- (9CI) (CA INDEX NAME)




RN 331630-70-7 CAPLUS

CN Acetamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]- (9CI) (CA INDEX NAME)




RN 331630-74-1 CAPLUS

CN Acetic acid, [[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 331630-75-2 CAPLUS

CN Propanoic acid, 3-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 331630-77-4 CAPLUS

CN Acetamide, N-[4,4-diphenyl-7-(4-phenyl-1-piperidinyl)heptyl]- (9CI) (CA INDEX NAME)




RN 331630-81-0 CAPLUS

CN Benzeneacetamide, N-[4,4-diphenyl-7-(4-phenyl-1-piperidinyl)heptyl]- (9CI) (CA INDEX NAME)




RN 331630-84-3 CAPLUS

CN Carbamic acid, [2-[[5-[4-(3-fluorophenyl)-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 331630-85-4 CAPLUS

CN Carbamic acid, [2-[[5-[4-(2-fluorophenyl)-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 331630-86-5 CAPLUS

CN Carbamic acid, [2-[[5-[4-(2-methoxyphenyl)-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 331630-87-6 CAPLUS

CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-1-[[2-(3-pyridinyl)-1-



pyrrolidiny]carbonyl]- (9CI) (CA INDEX NAME)



IT 331629-60-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of diarylalkanediamine derivs. as melanin concentrating hormone (MCH)

antagonists for treating MCH-caused diseases)

RN 331629-60-8 CAPLUS

CN Acetamide, 2-amino-N-[2,2-diphenyl-5-(4-phenyl-1-piperidiny]pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

REFERENCE COUNT:

12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN  
GI



I

AB Ligands for the CCR1 receptor (MIP-1 $\alpha$  and RANTES) have been implicated in a number of chronic inflammatory diseases, most notably multiple sclerosis and rheumatoid arthritis. Because these ligands share a common receptor, CCR1, we sought to discover antagonists for this receptor as an approach to treating these disorders. A novel series of 4-hydroxypiperidines has been discovered by high throughput screening (HTS) which potently inhibits the binding of MIP-1 $\alpha$  and RANTES to the recombinant human CCR1 chemokine receptor. The structure-activity relationships of various segments of this template are described as the initial HTS lead was optimized synthetically to the highly potent receptor antagonist I. This compound has been shown to have at least 200-fold selectivity for inhibition of CCR1 over other human 7-TM receptors, including other chemokine receptors. In addition, data obtained from in vitro functional assays demonstrate the functional antagonism of compound I and structurally related analogs against the CCR1 receptor in a concentration dependent manner. The discovery and optimization of potent and selective CCR1 receptor antagonists represented by compound I potentially represent a novel approach to the treatment of chronic inflammatory diseases.

ACCESSION NUMBER: 1999:643381 CAPLUS

DOCUMENT NUMBER: 132:8707

TITLE: Discovery of Novel Non-Peptide CCR1 Receptor Antagonists

AUTHOR(S): Ng, Howard P.; May, Karen; Bauman, John G.; Ghannam, Ameen; Islam, Imadul; Liang, Meina; Horuk, Richard; Hesselgesser, Joseph; Snider, R. Michael; Perez, H. Daniel; Morrissey, Michael M.

CORPORATE SOURCE: Departments of Discovery Research and Immunology, Berlex Biosciences, Richmond, CA, 94804-0099, USA

SOURCE: Journal of Medicinal Chemistry (1999), 42(22), 4680-4694

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 193542-13-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of and structure-activity studies on non-peptide CCR1 receptor antagonists)

RN 193542-13-1 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-4-piperidinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

32

THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds., e.g. I [X, Y = (halo-substituted) Ph, pyridyl; R1 = (halogenated) alkyl, etc.], are prepared In an in vitro test for RANTES antagonism, the title compound II showed IC50 of 0.02  $\mu$ M.

ACCESSION NUMBER: 1999:188995 CAPLUS

DOCUMENT NUMBER: 130:237480

TITLE: Preparation and formulation of hydroxypiperidine derivatives as MIP-1 $\alpha$  and RANTES antagonists

INVENTOR(S): Kato, Kaneyoshi; Tsukamoto, Tetsuya; Honda, Susumu; Watanabe, Masanori

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 39 pp.

CODEN: JKXXAF.

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11071350	A2	19990316	JP 1998-168003	19980616
PRIORITY APPLN. INFO.:			JP 1997-160260	19970617

OTHER SOURCE(S): MARPAT 130:237480


IT 221338-86-9P 221338-90-5P 221338-95-0P  
221339-00-0P 221339-03-3P 221339-07-7P  
221339-11-3P 221339-13-5P 221339-17-9P  
221339-21-5P 221339-25-9P 221339-30-6P  
221339-32-8P 221339-34-0P 221339-47-5P  
221339-50-0P 221339-54-4P 221339-69-1P  
221339-72-6P 221339-75-9P 221339-78-2P  
221339-79-3P 221339-81-7P 221339-82-8P  
221339-83-9P 221339-84-0P 221339-86-2P  
221339-87-3P 221339-89-5P 221339-90-8P  
221339-92-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydroxypiperidine derivs. as MIP-1 $\alpha$  and RANTES antagonists)


RN 221338-86-9 CAPLUS

CN Carbamic acid, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, 4-piperidinyl ester (9CI) (CA INDEX NAME)




RN 221338-90-5 CAPLUS

CN Carbamic acid, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, 1-[(ethylamino)carbonyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)




RN 221338-95-0 CAPLUS

CN Carbamic acid, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, 1-(3-pyridinylcarbonyl)-4-piperidinyl ester (9CI) (CA INDEX NAME)



RN 221339-00-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]amino]-, 2-chloroethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A


PAGE 1-B

---CH<sub>2</sub>Cl

RN 221339-03-3 CAPLUS


CN 4-Piperidinamine, 1-[(acetyloxy)acetyl]-N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 221339-07-7 CAPLUS

CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-1-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 221339-11-3 CAPLUS

CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-1-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 221339-13-5 CAPLUS


CN 4-Piperidinamine, 1-benzoyl-N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 221339-17-9 CAPLUS  
 CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-1-(hydroxyacetyl)- (9CI) (CA INDEX NAME)




RN 221339-21-5 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]amino]-, 2-(1-pyrrolidiny)ethyl ester (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B




RN 221339-25-9 CAPLUS  
 CN 3-Pyridinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, dihydrochloride (9CI) (CA INDEX NAME)




2 HCl

RN 221339-30-6 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[2-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethylidene]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 221339-32-8 CAPLUS  
 CN 4-Piperidineacetamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 221339-34-0 CAPLUS  
 CN Acetamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-2-(4-piperidinylidene)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 221339-47-5 CAPLUS  
 CN 4-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-bis(4-fluorophenyl)pentyl]-1-(4-pyridinylcarbonyl)-, dihydrochloride (9CI) (CA INDEX NAME)






●2 HCl

RN 221339-50-0 CAPLUS  
 CN 4-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2-(4-fluorophenyl)-2-phenylpentyl]-1-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 221339-54-4 CAPLUS  
 CN 4-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2-(4-fluorophenyl)-2-phenylpentyl]-1-(4-pyridinylcarbonyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 221339-69-1 CAPLUS

CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-bis(4-fluorophenyl)pentyl]amino]carbonyl]-1-(4-pyridinylcarbonyl)- (9CI)  
(CA INDEX NAME)




RN 221339-72-6 CAPLUS

CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-bis(4-fluorophenyl)pentyl]amino]carbonyl]-1-(4-pyridinylcarbonyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 221339-75-9 CAPLUS  
 CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-bis(4-fluorophenyl)pentyl]-N'-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)




RN 221339-78-2 CAPLUS  
 CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-bis(4-fluorophenyl)pentyl]amino]carbonyl]-1-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 221339-79-3 CAPLUS

CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2-(4-fluorophenyl)-2-phenylpentyl]amino]carbonyl]-1-(4-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 221339-81-7 CAPLUS


CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2-(4-fluorophenyl)-2-phenylpentyl]amino]carbonyl]-1-(4-pyridinylcarbonyl)-, dihydrochloride (9CI) (CA INDEX NAME)



2 HCl


RN 221339-82-8 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2-(4-fluorophenyl)-2-phenylpentyl]-N'-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)



RN 221339-83-9 CAPLUS


CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2-(4-fluorophenyl)-2-phenylpentyl]-N'-(3-hydroxypropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 221339-84-0 CAPLUS

CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2-(4-fluorophenyl)-2-phenylpentyl]amino]carbonyl]-1-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 221339-86-2 CAPLUS


CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2-(4-fluorophenyl)-2-phenylpentyl]amino]carbonyl]-1-(3-pyridinylcarbonyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 221339-87-3 CAPLUS


CN Urea, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-bis(4-fluorophenyl)pentyl]- (9CI) (CA INDEX NAME)



RN 221339-89-5 CAPLUS

CN Urea, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-bis(4-


fluorophenyl)pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 221339-90-8 CAPLUS

CN Urea, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2-(4-fluorophenyl)-2-phenylpentyl]- (9CI) (CA INDEX NAME)



RN 221339-92-0 CAPLUS

CN Urea, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2-(4-fluorophenyl)-2-phenylpentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl


IT 193541-41-2P 193542-03-9P 193542-13-1P  
 221340-08-5P 221340-17-6P 221340-45-0P  
 221340-47-2P 221340-49-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(preparation of hydroxypiperidine derivs. as MIP-1 $\alpha$  and RANTES  
 antagonists)


RN 193541-41-2 CAPLUS

CN Carbamic acid, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-  
 diphenylpentyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 193542-03-9 CAPLUS

CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-  
 diphenylpentyl]amino]carbonyl]-1-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



RN 193542-13-1 CAPLUS


CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-  
 diphenylpentyl]-N'-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 221340-08-5 CAPLUS


CN Carbamic acid, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-bis(4-  
 fluorophenyl)pentyl]-, phenyl ester (9CI) (CA INDEX NAME)






RN 221340-17-6 CAPLUS

CN Carbamic acid, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2-(4-fluorophenyl)-2-phenylpentyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 221340-45-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]oxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 221340-47-2 CAPLUS

CN Carbamic acid, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, 2-chloroethyl ester (9CI) (CA INDEX NAME)



RN 221340-49-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

AB The CC chemokines macrophage inflammatory protein-1 $\alpha$  (MIP-1 $\alpha$ ) and RANTES (regulated on activation normal T cell expressed) have been implicated in rheumatoid arthritis and multiple sclerosis. Since their effects are mediated through the CCR1 chemokine receptor, we set up a small mol. CCR1 antagonist program to search for inhibitors. Through high capacity screening we discovered a number of 4-hydroxypiperidine compds. with CCR1 antagonist activity and report their synthesis and in vitro pharmacol. here. Scatchard anal. of the competition binding data revealed that the compds. had  $K_i$  values ranging from 40 to 4000 nM. The pharmacol. profile of the most potent member of this series, (2,2-diphenyl-5-(4-chlorophenyl)piperidinyl)valeronitrite (I), was further evaluated. Compound I showed concentration-dependent inhibition of MIP-1 $\alpha$ -induced extracellular acidification and  $Ca^{2+}$  mobilization demonstrating functional antagonism. When given alone, the compound did not elicit any responses, indicating the absence of intrinsic agonist activity. Compound I inhibited MIP-1 $\alpha$ - and RANTES-induced migration in peripheral blood mononuclear cells in a dose-responsive manner. Selectivity testing against a panel of seven transmembrane domain receptors indicated that compound I is inactive on a number of receptors at concns. up to 10  $\mu$ M. This is the first description of CCR1 receptor antagonists that may be useful in the treatment of chronic inflammatory diseases involving MIP-1 $\alpha$ , RANTES, and CCR1.


ACCESSION NUMBER: 1998:400595 CAPLUS  
 DOCUMENT NUMBER: 129:144656  
 TITLE: Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor  
 AUTHOR(S): Hesselgesser, Joseph; Ng, Howard P.; Liang, Meina; Zheng, Wei; May, Karen; Bauman, John G.; Monahan, Sean; Islam, Imadul; Wei, Guo Ping; Ghannam, Ameen; Taub, Dennis D.; Rosser, Mary; Snider, R. Michael; Morrissey, Michael M.; Perez, H. Daniel; Horuk, Richard  
 CORPORATE SOURCE: Department of Immunology, Berlex BioSciences, Richmond, CA, 94806, USA  
 SOURCE: Journal of Biological Chemistry (1998), 273(25), 15687-15692  
 CODEN: JBCHA3; ISSN: 0021-9258  
 PUBLISHER: American Society for Biochemistry and Molecular Biology  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

IT 193542-13-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and characterization of 4-hydroxypiperidine compds. as functional antagonists of CCR1 chemokine receptor)

RN 193542-13-1 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-4-piperidinyl- (9CI) (CA INDEX NAME)



02/13/2004


10088768.trn

REFERENCE COUNT:

29

THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN  
GI



AB Compds. which are MIP-1 $\alpha$ /RANTES-receptor antagonists are disclosed, specifically I [Ar1, Ar2 = (un)substituted aromatic group; Q1, Q2 = (un)substituted divalent C1-6 aliphatic hydrocarbon group which may have either O or S within the C chain; R1 = H, (un)substituted alkyl or (un)substituted alkylcarbonyl; R2 = (un)substituted hydrocarbon group or (un)substituted acyl; or NR1R2 = (un)substituted N-containing heterocyclic; NZ = (un)substituted N-containing mono- or fused heterocyclic group], and salts thereof. The compds. are useful for therapy or prophylaxis of inflammatory, allergic, and other diseases. Over 120 title compds., and a variety of intermediates, were prepared. For instance, N-alkylation of 4-(4-chlorophenyl)-4-hydroxypiperidine by 5-(formylamino)-1-iodo-4,4-diphenylpentane in MeCN in the presence of K2CO3 at 60° gave title compound II, isolated as the monohydrochloride (III). III displaced 125I-RANTES from human RANTES receptors in vitro with an IC50 of 0.04  $\mu$ M, vs. 3  $\mu$ M for ioperamide.

ACCESSION NUMBER: 1997:543479 CAPLUS  
DOCUMENT NUMBER: 127:161698  
TITLE: Heterocyclic diphenylmethane derivatives as MIP-1 $\alpha$ /RANTES receptor antagonists  
INVENTOR(S): Kato, Kaneyoshi; Yamamoto, Mitsuo; Honda, Susumu; Fujisawa, Tomoyuki  
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan; Kato, Kaneyoshi; Yamamoto, Mitsuo; Honda, Susumu; Fujisawa, Tomoyuki  
SOURCE: PCT Int. Appl., 250 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9724325	A1	19970710	WO 1996-JP3820	19961226
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9712083	A1	19970728	AU 1997-12083	19961226
JP 10081665	A2	19980331	JP 1996-349136	19961227
PRIORITY APPLN. INFO.:			JP 1995-343905	19951228
			JP 1996-187375	19960717
			WO 1996-JP3820	19961226
OTHER SOURCE(S):			MARPAT 127:161698	


IT 193542-71-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heterocyclic diphenylmethane derivs. as MIP-1 $\alpha$ /RANTES receptor antagonists)

RN 193542-71-1 CAPLUS

CN Propanamide, 3-chloro-N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]- (9CI) (CA INDEX NAME)



IT 193541-41-2P 193541-68-3P 193541-69-4P

193541-72-9P 193541-76-3P 193542-03-9P

193542-13-1P 193542-43-7P 193542-44-8P


193542-45-9P 193546-11-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of heterocyclic diphenylmethane derivs. as MIP-1 $\alpha$ /RANTES receptor antagonists)


RN 193541-41-2 CAPLUS

CN Carbamic acid, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 193541-68-3 CAPLUS

CN Carbamic acid, [3-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 193541-69-4 CAPLUS


CN Propanamide, 3-amino-N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 193541-72-9 CAPLUS

CN Carbamic acid, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-5-oxo-2,2-diphenylpentyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 193541-76-3 CAPLUS

CN Butanoic acid, 4-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-5-oxo-2,2-diphenylpentyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 193542-03-9 CAPLUS

CN 4-Piperidinamine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-1-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 193542-13-1 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-4-piperidinyl- (9CI) (CA INDEX NAME)




RN 193542-43-7 CAPLUS

CN Butanoic acid, 4-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 193542-44-8 CAPLUS


CN Formamide, N-[2,2-bis(4-chlorophenyl)-5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]pentyl]- (9CI) (CA INDEX NAME)



RN 193542-45-9 CAPLUS




CN Butanoic acid, 4-[[2,2-bis(4-chlorophenyl)-5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]pentyl]amino]-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 193546-11-1 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(3-hydroxypropyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 173272-79-2P 193541-23-0P 193541-24-1P  
 193541-25-2P 193541-26-3P 193541-27-4P  
 193541-29-6P 193541-30-9P 193541-31-0P  
 193541-32-1P 193541-33-2P 193541-35-4P  
 193541-36-5P 193541-37-6P 193541-38-7P  
 193541-39-8P 193541-43-4P 193541-44-5P  
 193541-45-6P 193541-47-8P 193541-48-9P  
 193541-49-0P 193541-50-3P 193541-51-4P  
 193541-52-5P 193541-53-6P 193541-54-7P  
 193541-55-8P 193541-56-9P 193541-57-0P  
 193541-58-1P 193541-59-2P 193541-65-0P  
 193541-66-1P 193541-67-2P 193541-70-7P  
 193541-71-8P 193541-73-0P 193541-74-1P  
 193541-75-2P 193541-77-4P 193541-78-5P  
 193541-83-2P 193541-84-3P 193541-85-4P  
 193541-86-5P 193541-87-6P 193541-88-7P  
 193541-89-8P 193541-90-1P 193541-91-2P  
 193541-92-3P 193541-93-4P 193541-94-5P  
 193541-95-6P 193541-96-7P 193541-97-8P  
 193541-98-9P 193541-99-0P 193542-00-6P

193542-01-7P 193542-02-8P 193542-04-0P  
 193542-05-1P 193542-06-2P 193542-07-3P  
 193542-08-4P 193542-09-5P 193542-12-0P  
 193542-14-2P 193542-15-3P 193542-16-4P  
 193542-17-5P 193542-18-6P 193542-19-7P  
 193542-20-0P 193542-21-1P 193542-22-2P  
 193542-23-3P 193542-24-4P 193542-25-5P  
 193542-26-6P 193542-27-7P 193542-28-8P  
 193542-29-9P 193542-30-2P 193542-31-3P  
 193542-32-4P 193542-33-5P 193542-34-6P  
 193542-35-7P 193542-36-8P 193542-37-9P  
 193542-38-0P 193542-39-1P 193542-40-4P  
 193542-41-5P 193542-42-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of heterocyclic diphenylmethane derivs. as MIP-1 $\alpha$ /RANTES receptor antagonists)

RN 173272-79-2 CAPLUS


CN Formamide, N-[5-[4-(4-fluorophenyl)-1-piperazinyl]-2,2-diphenylpentyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 193541-23-0 CAPLUS


CN Formamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193541-24-1 CAPLUS

CN Formamide, N-[5-(4-hydroxy-4-phenyl-1-piperidinyl)-2,2-diphenylpentyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193541-25-2 CAPLUS  
 CN Formamide, N-[5-[4-hydroxy-4-[4-(trifluoromethyl)phenyl]-1-piperidinyl]-2,2-diphenylpentyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193541-26-3 CAPLUS  
 CN Formamide, N-[5-[4-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193541-27-4 CAPLUS  
 CN Formamide, N-[5-[4-(3,5-dichlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193541-29-6 CAPLUS  
CN Formamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]- (9CI) (CA INDEX NAME)




RN 193541-30-9 CAPLUS  
CN Formamide, N-[5-[4-(4-chlorophenyl)-1-piperidinyl]-2,2-diphenylpentyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193541-31-0 CAPLUS  
CN Formamide, N-[7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-4,4-diphenylheptyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193541-32-1 CAPLUS  
 CN Formamide, N-[5-[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193541-33-2 CAPLUS  
 CN Formamide, N-[5-[4-hydroxy-4-(4-methoxyphenyl)-1-piperidinyl]-2,2-diphenylpentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193541-35-4 CAPLUS  
 CN Acetamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193541-36-5 CAPLUS


CN Butanamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-3-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193541-37-6 CAPLUS


CN Butanoic acid, 4-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-4-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193541-38-7 CAPLUS

CN Butanoic acid, 4-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-4-oxo- (9CI) (CA INDEX NAME)




RN 193541-39-8 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-ethyl- (9CI) (CA INDEX NAME)



RN 193541-43-4 CAPLUS


CN Acetic acid, [[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193541-44-5 CAPLUS


CN Propanoic acid, 3-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-3-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193541-45-6 CAPLUS

CN Pentanoic acid, 5-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 193541-47-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193541-48-9 CAPLUS


CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)





RN 193541-49-0 CAPLUS


CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(4-hydroxybutyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193541-50-3 CAPLUS

CN β-Alanine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 193541-51-4 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 193541-52-5 CAPLUS


CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[3-(diethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 193541-53-6 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 193541-54-7 CAPLUS  
 CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidiny]-2,2-diphenylpentyl]-N'-[2-(1-piperidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 193541-55-8 CAPLUS  
 CN Ethanesulfonamide, 2-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidiny]-2,2-diphenylpentyl]amino]carbonyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193541-56-9 CAPLUS  
 CN Ethanesulfonic acid, 2-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidiny]-2,2-diphenylpentyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 193541-57-0 CAPLUS

CN Carbamic acid, [5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]- (9CI) (CA INDEX NAME)




RN 193541-58-1 CAPLUS

CN Propanoic acid, 3-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 193541-59-2 CAPLUS


CN Pentanoic acid, 5-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]-5-oxo- (9CI) (CA INDEX NAME)




RN 193541-65-0 CAPLUS

CN 1-Pyrrolidinepropanamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-3-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 193541-66-1 CAPLUS  
 CN 1-Pyrrolidinepropanamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 193541-67-2 CAPLUS  
 CN Propanamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 193541-70-7 CAPLUS  
 CN Propanamide, 3-(acetylamino)-N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-

piperidinyll]-2,2-diphenylpentyl]- (9CI) (CA INDEX NAME)




RN 193541-71-8 CAPLUS

CN Propanamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyll]-2,2-diphenylpentyl]-3-[(1-oxopropyl)amino]- (9CI) (CA INDEX NAME)




RN 193541-73-0 CAPLUS

CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[5-[[[(3-hydroxypropyl)amino]carbonyl]amino]-1-oxo-4,4-diphenylpentyl]- (9CI) (CA INDEX NAME)



RN 193541-74-1 CAPLUS


CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[5-[[[2-(dimethylamino)ethyl]amino]carbonyl]amino]-1-oxo-4,4-diphenylpentyl]- (9CI) (CA INDEX NAME)



RN 193541-75-2 CAPLUS


CN Acetamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyll]-5-oxo-2,2-

diphenylpentyl]- (9CI) (CA INDEX NAME)



RN 193541-77-4 CAPLUS


CN Butanoic acid, 4-[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-5-oxo-2,2-diphenylpentyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 193541-78-5 CAPLUS


CN 4-Piperidinol, 4-(4-chlorophenyl)-1-[1-oxo-5-[[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]carbonyl]amino]-4,4-diphenylpentyl]- (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A



RN 193541-83-2 CAPLUS


CN Formamide, N-[2,2-bis(4-chlorophenyl)-5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193541-84-3 CAPLUS


CN Butanoic acid, 4-[[2,2-bis(4-chlorophenyl)-5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]pentyl]amino]-4-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193541-85-4 CAPLUS

CN Butanoic acid, 4-[[2,2-bis(4-chlorophenyl)-5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidiny]pentyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 193541-86-5 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidiny]-2,2-diphenylpentyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 193541-87-6 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 193541-88-7 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 193541-89-8 CAPLUS

CN Urea, N-(3-aminopropyl)-N'-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 193541-90-1 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(5-hydroxypentyl)- (9CI) (CA INDEX NAME)




RN 193541-91-2 CAPLUS

CN Urea, N'-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N-[2-(dimethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 193541-92-3 CAPLUS

CN Urea, N'-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N-methyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 193541-93-4 CAPLUS

CN Urea, N'-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N-(2-hydroxyethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 193541-94-5 CAPLUS

CN Acetamide, N-[2-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 193541-95-6 CAPLUS


CN Butanoic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 193541-96-7 CAPLUS


CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

NAME)




RN 193541-97-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 193541-98-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 193541-99-0 CAPLUS


CN 3H-3-Benzazepine-3-carboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-1,2,4,5-tetrahydro- (9CI) (CA INDEX NAME)




RN 193542-00-6 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-3-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 193542-01-7 CAPLUS  
 CN Carbamic acid, [1-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 193542-02-8 CAPLUS  
 CN 1-Piperidineacetic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 193542-04-0 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-4-formyl-, (9CI) (CA INDEX NAME)




RN 193542-05-1 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-4-(3-hydroxypropyl)-, (9CI) (CA INDEX NAME)



RN 193542-06-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 193542-07-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-




2,2-diphenylpentyl]-4-[2-(4-morpholinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 193542-08-4 CAPLUS

CN  $\beta$ -Alanine, N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 193542-09-5 CAPLUS

CN Butanoic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 193542-12-0 CAPLUS

CN 4-Piperidinol, 1-[5-[[[3-[(aminocarbonyl)oxy]propyl]amino]carbonyl]amino]-4,4-diphenylpentyl]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 193542-14-2 CAPLUS  
 CN 1-Piperidinebutanoic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]amino]- $\gamma$ -oxo-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



RN 193542-15-3 CAPLUS  
 CN 1-Piperidinecarboxamide, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]amino]-N-ethyl- (9CI) (CA INDEX NAME)




RN 193542-16-4 CAPLUS  
 CN 4-Piperidinamine, 1-acetyl-N-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 193542-17-5 CAPLUS  
 CN Glycine, N-[[4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]amino]-1-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 193542-18-6 CAPLUS

CN 1-Piperidinepropanoic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]amino]- $\beta$ -oxo-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 193542-19-7 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-(1-ethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 193542-20-0 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[1-(2-hydroxyethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 193542-21-1 CAPLUS

CN 1-Piperidinepropanoic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

---- OEt


RN 193542-22-2 CAPLUS

CN Urea, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N'-[1-(3-hydroxypropyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 193542-23-3 CAPLUS

CN 4-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 193542-24-4 CAPLUS  
 CN 4-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-1-ethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 193542-25-5 CAPLUS  
 CN 1-Piperidineacetic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 193542-26-6 CAPLUS  
 CN 4-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-1-[2-(4-morpholinyl)ethyl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




●3 HCl

PAGE 1-B

Cl

RN 193542-27-7 CAPLUS


CN 4-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-1-[2-(dimethylamino)ethyl]-, trihydrochloride (9CI)  
(CA INDEX NAME)



●3 HCl

RN 193542-28-8 CAPLUS


CN 1,4-Piperidinedicarboxamide, N4-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N1-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193542-29-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193542-30-2 CAPLUS

CN 1,4-Piperidinedicarboxamide, N4-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N1-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




HCl

RN 193542-31-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-(4-chlorobenzoyl)-N-[5-[4-(4-chlorophenyl)-4-


hydroxy-1-piperidinyll]-2,2-diphenylpentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 193542-32-4 CAPLUS

CN 1-Piperidinepropanoic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyll]-2,2-diphenylpentyl]amino]carbonyl]-β-oxo-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 193542-33-5 CAPLUS

CN 1-Piperidinebutanoic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyll]-2,2-diphenylpentyl]amino]carbonyl]-γ-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



PAGE 1-A




● HCl

PAGE 1-B

--- OMe

RN 193542-34-6 CAPLUS


CN 4-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-1-(3-pyridinylcarbonyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 193542-35-7 CAPLUS


CN 4-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-1-[4-(dimethylamino)-1-oxobutyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 193542-36-8 CAPLUS


CN 4-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-1-propyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 193542-37-9 CAPLUS


CN 4-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-1-(3-pyridinylacetyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 193542-38-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 193542-39-1 CAPLUS

CN 4-Piperidinecarboxamide, N-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]- (9CI) (CA INDEX NAME)




RN 193542-40-4 CAPLUS

CN 1,4-Piperidinedicarboxamide, N4-[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]-N1-ethyl- (9CI) (CA INDEX NAME)




RN 193542-41-5 CAPLUS

CN 1-Piperidinepropanoic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-β-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 193542-42-6 CAPLUS  
CN 1-Piperidinebutanoic acid, 4-[[[5-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-2,2-diphenylpentyl]amino]carbonyl]-γ-oxo-, methyl ester  
(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

---- OMe

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN  
GI



AB The title compds. I [Ar1, Ar2 = aromatic moiety; P, Q = divalent aliphatic hydrocarbon; R1, R2 = H, acyl, etc.; or NR1R2 = N-containing heterocycle; R3 = hydrocarbon, etc.; j = 1 or 2] are prepared. The title compound II in vitro showed potent inhibiting activity against calcium uptake into cerebral cortex cells.

ACCESSION NUMBER: 1996:666869 CAPLUS  
DOCUMENT NUMBER: 125:300606  
TITLE: Preparation and formulation of aryl sulfonamides as calcium and serotonin uptake inhibitors  
INVENTOR(S): Kato, Kaneyoshi; Sugiura, Yoshihiro; Nagai, Yasuo  
PATENT ASSIGNEE(S): Takeda Chemical Industries Ltd, Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 51 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08208595	A2	19960813	JP 1995-296586	19951115
PRIORITY APPLN. INFO.:			JP 1994-286244	19941121


OTHER SOURCE(S): MARPAT 125:300606

IT 173272-79-2P 173272-81-6P 173272-82-7P  
173272-84-9P 179312-63-1P 179312-83-5P  
179312-85-7P 179312-88-0P 179312-89-1P  
182807-77-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of aryl sulfonamides as calcium and serotonin uptake inhibitors)


RN 173272-79-2 CAPLUS

CN Formamide, N-[5-[4-(4-fluorophenyl)-1-piperazinyl]-2,2-diphenylpentyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 173272-81-6 CAPLUS  
 CN Formamide, N-[2-(4-chlorophenyl)-2-phenyl-5-(4-phenyl-1-piperazinyl)pentyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 173272-82-7 CAPLUS  
 CN Formamide, N-[2-(4-chlorophenyl)-2-phenyl-5-(4-phenyl-1-piperidinyl)pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 173272-84-9 CAPLUS  
 CN Formamide, N-[2-(4-chlorophenyl)-5-[4-(4-fluorophenyl)-1-piperazinyl]-2-phenylpentyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 179312-63-1 CAPLUS


CN Formamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidinyl)pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 179312-83-5 CAPLUS


CN Formamide, N-[2-(4-methoxyphenyl)-2-phenyl-5-(4-phenyl-1-piperidinyl)pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 179312-85-7 CAPLUS


CN Formamide, N-[2,2-bis(4-chlorophenyl)-5-[4-(4-fluorophenyl)-1-piperazinyl]pentyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 179312-88-0 CAPLUS


CN Formamide, N-[6-[4-(4-chlorophenyl)-2,2-diphenylhexyl]-4-(4-fluorophenyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 179312-89-1 CAPLUS

CN Formamide, N-[6-[4-(4-fluorophenyl)-1-piperazinyl]-3,3-diphenylhexyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 182807-77-8 CAPLUS

CN Formamide, N-[3,3-diphenyl-6-(4-phenyl-1-piperidinyl)hexyl]-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN  
 GI For diagram(s), see printed CA Issue.  
 AB The title compds. [I; Ar1, Ar2 = (un)substituted aryl; P, Q = divalent aliphatic hydrocarbonyl having  $\geq 2$  carbon atoms and optionally having ether O or S in the chain; R1, R3 = COR, CONHR, hydrocarbonyl; R = hydrocarbonyl, heterocyclyl; R2, R4 = H, alkyl; group; NR1R2 and/or NR3R4 may form a nitrogen-containing heterocyclic group; j = 0, 1], which demonstrate high gonadotropin-releasing hormone (GnRH) receptor antagonist activity, useful in the treatment of hormone-dependent diseases [e.g., prostate cancer (no data), endometriosis (no data), etc. (no data)], are prepared and I-containing formulations presented. Thus, II was prepared and demonstrated a IC50 of 0.08  $\mu\text{M}$  against the binding of 125I-leuprolerin to human GnRH receptors.

ACCESSION NUMBER: 1996:466898 CAPLUS  
 DOCUMENT NUMBER: 125:114489  
 TITLE: Preparation of heterocyclic amine-compound antagonists of gonadotropin-releasing hormone receptors  
 INVENTOR(S): Kato, Kaneyoshi; Sugiura, Yoshihiro; Kato, Koichi  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: Eur. Pat. Appl., 123 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 712845	A1	19960522	EP 1995-308331	19951121
EP 712845	B1	20011017		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08253447	A2	19961001	JP 1995-300330	19951117
CA 2163325	AA	19960522	CA 1995-2163325	19951120
US 5633248	A	19970527	US 1995-561282	19951121
AT 207058	E	20011115	AT 1995-308331	19951121

PRIORITY APPLN. INFO.: JP 1994-286245 A 19941121


OTHER SOURCE(S): MARPAT 125:114489

IT 173272-79-2P 173272-81-6P 173272-82-7P  
 173272-84-9P 179312-63-1P 179312-83-5P  
 179312-85-7P 179312-88-0P 179312-89-1P  
 179313-27-0P 179313-28-1P 179313-29-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of heterocyclic amine-compound antagonists of gonadotropin-releasing hormone receptors)


RN 173272-79-2 CAPLUS

CN Formamide, N-[5-[4-(4-fluorophenyl)-1-piperazinyl]-2,2-diphenylpentyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 173272-81-6 CAPLUS  
 CN Formamide, N-[2-(4-chlorophenyl)-2-phenyl-5-(4-phenyl-1-piperazinyl)pentyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 173272-82-7 CAPLUS  
 CN Formamide, N-[2-(4-chlorophenyl)-2-phenyl-5-(4-phenyl-1-piperidinyl)pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 173272-84-9 CAPLUS  
 CN Formamide, N-[2-(4-chlorophenyl)-5-[4-(4-fluorophenyl)-1-piperazinyl]-2-phenylpentyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 179312-63-1 CAPLUS


CN Formamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperidiny]pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 179312-83-5 CAPLUS


CN Formamide, N-[2-(4-methoxyphenyl)-2-phenyl-5-(4-phenyl-1-piperidiny]pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 179312-85-7 CAPLUS


CN Formamide, N-[2,2-bis(4-chlorophenyl)-5-[4-(4-fluorophenyl)-1-piperazinyl]pentyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 179312-88-0 CAPLUS


CN Formamide, N-[6-[4-(4-chlorophenyl)-2,2-diphenylhexyl]-4-(4-fluorophenyl)-1-piperazinyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 179312-89-1 CAPLUS


CN Formamide, N-[6-[4-(4-fluorophenyl)-1-piperazinyl]-3,3-diphenylhexyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 179313-27-0 CAPLUS


CN Benzenepropanamide, N-[4,4-diphenyl-7-(4-phenyl-1-piperidinyl)heptyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 179313-28-1 CAPLUS


CN Benzenepropanamide, N-[7-[4-(3-methoxyphenyl)-1-piperidinyl]-4,4-diphenylheptyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 179313-29-2 CAPLUS

CN Benzenepropanamide, 4-methoxy-N-[7-[4-(4-methoxyphenyl)-1-piperidinyl]-4,4-diphenylheptyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN  
GI



I

AB Title compds. (I; Ar = aromatic group; R1, R2, R3 = H, acyl, hydrocarbyl; R1R2N = heterocyclyl; m = 1-6; n = 2, 3; dotted line = optional double bond; X = O, NR3, N:), were prepared Thus, 4-(2-iodoethyl)-4-phenylisochroman and imidazole were stirred with K2CO3 in MeCN for 4 days at 60° to give 4-phenyl-4-[2-(1-imidazolyl)ethyl]isochroman, isolated as the hydrochloride. I inhibited 5-HT uptake in rat brain preps. with IC50 = 0.03-1.0 µM. I drug formulations are given.

ACCESSION NUMBER: 1995:995626 CAPLUS

DOCUMENT NUMBER: 124:145926

TITLE: Preparation of aminoalkylisochromans, -isoquinolines, and related compounds as gonadotropin-releasing hormone antagonists, calcium antagonists, and/or monoamine uptake inhibitors.

INVENTOR(S): Kato, Kaneyoshi; Sugiura, Yoshihiro; Kato, Koichi; Nagai, Yasuo

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Eur. Pat. Appl., 104 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 679642	A1	19951102	EP 1995-106189	19950426
EP 679642	B1	19991110		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5607939	A	19970304	US 1995-428499	19950425
AT 186530	E	19991115	AT 1995-106189	19950426
CA 2148047	AA	19951029	CA 1995-2148047	19950427
JP 08012650	A2	19960116	JP 1995-103389	19950427
US 5654296	A	19970805	US 1996-760904	19961206
PRIORITY APPLN. INFO.:			JP 1994-114054	19940428
			JP 1994-92769	19940428
			US 1995-428499	19950425

OTHER SOURCE(S): MARPAT 124:145926


IT 173272-96-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminoalkylisochromans, -isoquinolines, and related compds. as gonadotropin-releasing hormone antagonists, calcium antagonists, and/or monoamine uptake inhibitors)

RN 173272-96-3 CAPLUS

CN Formamide, N-[4-[4-(4-fluorophenyl)-1-piperazinyl]-2,2-diphenylbutyl]-(9CI) (CA INDEX NAME)




IT 173272-65-6P 173272-74-7P 173272-79-2P  
173272-81-6P 173272-82-7P 173272-84-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoalkylisochromans, -isoquinolines, and related compds. as gonadotropin-releasing hormone antagonists, calcium antagonists, and/or monoamine uptake inhibitors)


RN 173272-65-6 CAPLUS

CN Formamide, N-[2,2-diphenyl-5-(4-phenyl-1-piperazinyl)pentyl]- (9CI) (CA INDEX NAME)



RN 173272-74-7 CAPLUS

CN Formamide, N-[4-[4-(4-fluorophenyl)-1-piperazinyl]-2,2-diphenylbutyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 173272-79-2 CAPLUS


CN Formamide, N-[5-[4-(4-fluorophenyl)-1-piperazinyl]-2,2-diphenylpentyl]-, dihydrochloride (9CI) (CA INDEX NAME)






● 2 HCl

RN 173272-81-6 CAPLUS  
 CN Formamide, N-[2-(4-chlorophenyl)-2-phenyl-5-(4-phenyl-1-piperazinyl)pentyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 173272-82-7 CAPLUS  
 CN Formamide, N-[2-(4-chlorophenyl)-2-phenyl-5-(4-phenyl-1-piperidinyl)pentyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 173272-84-9 CAPLUS  
 CN Formamide, N-[2-(4-chlorophenyl)-5-[4-(4-fluorophenyl)-1-piperazinyl]-2-phenylpentyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

02/13/2004

10088768.trn

=> d his

(FILE 'HOME' ENTERED AT 14:10:51 ON 13 FEB 2004)

FILE 'REGISTRY' ENTERED AT 14:11:03 ON 13 FEB 2004

L1 STRUCTURE UPLOADED

L2 STRUCTURE UPLOADED

L3 19 S L2

L4 19 S L1

L5 311 S L1 FUL

FILE 'CAPLUS' ENTERED AT 14:13:19 ON 13 FEB 2004

L6 9 S L5

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL-ESTIMATED COST

45.44

202.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-6.24

-6.24

STN INTERNATIONAL LOGOFF AT 14:16:59 ON 13 FEB 2004